Expertise in
42
conditions

Dr. Brenda W. Cooper

Internal Medicine
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Accepting New Patients
Expertise in
42
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Brenda Cooper is a primary care provider, practicing in Internal Medicine in Cleveland, Ohio.

Dr. Cooper is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Graft.

She is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 14 clinical trials. Dr. Cooper is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in OH

Hospital Affiliations

Uh Cleveland Medical Center
University Hospitals Ahuja Medical Center
Parma Community General Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Genetic
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Biological, Drug
Study Drugs: VOR33, Mylotarg
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

62 Total Publications

A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.
A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.
Journal: Leukemia & lymphoma
Published: August 07, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Christopher L. King
Internal Medicine
Expertise in
18
conditions
Dr. Christopher L. King
Internal Medicine

Office

36100 Jackson Rd, 
Chagrin Falls, OH 
 (10.1 miles away)
216-921-6728
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher King is a primary care provider, practicing in Internal Medicine in Chagrin Falls, Ohio. Dr. King is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lymphatic Filariasis, Spirurida Infections, Lymphedema, and Secernentea Infections. Dr. King is currently accepting new patients.

Expertise in
16
conditions
Dr. Kai M. Wang
Internal Medicine
Expertise in
16
conditions
Dr. Kai M. Wang
Internal Medicine

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-445-7277
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kai Wang is a primary care provider, practicing in Internal Medicine in Cleveland, Ohio. He has been practicing medicine for over 44 years. Dr. Wang is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pericarditis, Constrictive Pericarditis, Tricuspid Regurgitation, Coronary Artery Bypass Graft (CABG), and Aortic Valve Replacement. Dr. Wang is currently accepting new patients.

Expertise in
42
conditions
Dr. Natalie S. Evans
Internal Medicine
Expertise in
42
conditions
Dr. Natalie S. Evans
Internal Medicine

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
216-844-3800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Natalie Evans is a primary care provider, practicing in Internal Medicine in Cleveland, Ohio. Dr. Evans is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Deep Vein Thrombosis, Pulmonary Embolism, Superficial Thrombophlebitis, Embolectomy, and Thrombectomy. Dr. Evans is currently accepting new patients.

Frequently Asked Questions about Dr. Brenda W. Cooper

How do I make an appointment with Dr. Brenda W. Cooper?

You can book an appointment with Dr. Brenda W. Cooper by calling their office at 216-844-3951. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brenda W. Cooper a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brenda W. Cooper is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brenda W. Cooper specialize in?

While Dr. Brenda W. Cooper is a Internal Medicine, they have specific expertise in Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Brenda W. Cooper participate in research or clinical trials?

Yes. Dr. Brenda W. Cooper has published 62 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Brenda W. Cooper's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brenda W. Cooper accept my insurance?

Dr. Brenda W. Cooper accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-3951 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooper's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 24 Advanced Conditions
View All 79 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile